# Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.

> **NCT02831543** · PHASE3 · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 354 (estimated)

## Conditions studied

- Functional Dyspepsia

## Interventions

- **DRUG:** Motireb 5/100 mg
- **DRUG:** Mosapride citrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02831543
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2017-01
- **Final completion:** 2017-06
- **Target enrollment:** 354 (ESTIMATED)
- **Last updated:** 2016-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02831543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02831543, "Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT02831543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*